TY - JOUR
T1 - In vitro antiamyloidogenic properties of 1,4-naphthoquinones
AU - Bermejo-Bescós, Paloma
AU - Martín-Aragón, Sagrario
AU - Jiménez-Aliaga, Karim L.
AU - Ortega, Andrea
AU - Molina, María Teresa
AU - Buxaderas, Eduardo
AU - Orellana, Guillermo
AU - Csákÿ, Aurelio G.
N1 - Funding Information:
Andrea Ortega is a Ph.D. fellow and is supported by the MECESUP program from the Chile government (UCN0604). Projects UCM-910815 and CTQ2009-14124-C02-01 are gratefully acknowledged for financial support.
PY - 2010/9
Y1 - 2010/9
N2 - The aim of this study is to find out whether several 1,4-naphthoquinones (1,4-NQ) can interact with the amyloidogenic pathway of the amyloid precursor protein processing, particularly targeting at β-secretase (BACE), as well as at β-amyloid peptide (Aβ) aggregation and disaggregating preformed Aβ fibrils. Compounds bearing hydroxyl groups at the quinoid (2) or benzenoid rings (5, 6) as well as some 2- and 3-aryl derivatives (11-15) showed BACE inhibitory activity, without effect on amyloid aggregation or disaggregation. The halogenated compounds 8 and 10 were selective for the inhibition of amyloid aggregation. On the other hand, 1,4-naphthoquinone (1), 6-hydroxy-1,4-naphthoquinone (4) and 2-(3,4-dichlorophenyl)-1,4-naphthoquinone (26) did not show any BACE inhibitory activity but were active on amyloid aggregation and disaggregation preformed Aβ fibrils. Juglone (5-hydroxy-1,4-naphthoquinone (3), and 3-(p-hydroxyphenyl)-5-methoxy-1,4-napththoquinone (19) were active on all the three targets. Therefore, we suggest that 1,4-NQ derivatives, specially 3 and 19, should be explored as possible drug candidates or lead compounds for the development of drugs to prevent amyloid aggregation and neurotoxicity in Alzheimer's disease.
AB - The aim of this study is to find out whether several 1,4-naphthoquinones (1,4-NQ) can interact with the amyloidogenic pathway of the amyloid precursor protein processing, particularly targeting at β-secretase (BACE), as well as at β-amyloid peptide (Aβ) aggregation and disaggregating preformed Aβ fibrils. Compounds bearing hydroxyl groups at the quinoid (2) or benzenoid rings (5, 6) as well as some 2- and 3-aryl derivatives (11-15) showed BACE inhibitory activity, without effect on amyloid aggregation or disaggregation. The halogenated compounds 8 and 10 were selective for the inhibition of amyloid aggregation. On the other hand, 1,4-naphthoquinone (1), 6-hydroxy-1,4-naphthoquinone (4) and 2-(3,4-dichlorophenyl)-1,4-naphthoquinone (26) did not show any BACE inhibitory activity but were active on amyloid aggregation and disaggregation preformed Aβ fibrils. Juglone (5-hydroxy-1,4-naphthoquinone (3), and 3-(p-hydroxyphenyl)-5-methoxy-1,4-napththoquinone (19) were active on all the three targets. Therefore, we suggest that 1,4-NQ derivatives, specially 3 and 19, should be explored as possible drug candidates or lead compounds for the development of drugs to prevent amyloid aggregation and neurotoxicity in Alzheimer's disease.
KW - 1,4-Naphthoquinones
KW - Alzheimer's disease
KW - Amyloid aggregation
KW - Aβ fibrils
KW - β-Secretase (BACE)
UR - http://www.scopus.com/inward/record.url?scp=79953282113&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2010.08.038
DO - 10.1016/j.bbrc.2010.08.038
M3 - Artículo
C2 - 20709023
AN - SCOPUS:79953282113
SN - 0006-291X
VL - 400
SP - 169
EP - 174
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -